China-based biotechnology company HitGen has entered a drug discovery research collaboration with German firm Boehringer Ingelheim to discover new small molecule leads.
HitGen has set up a new platform for drug discovery research centred around Deoxyribonucleic acid (DNA)-encoded chemical libraries (DELs), which comprise more than 90 billion new and varied drug-like small molecule and macrocycle compounds.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
HitGen Board chairman and CEO Dr Jin Li said: “We are delighted to enter this collaboration with Boehringer Ingelheim, a major research based pharmaceutical company providing worldwide benefits to patients.
“This collaboration further emphasises the role of HitGen in the rapidly developing field of DNA-encoded chemistry.
“We will work closely with Boehringer Ingelheim scientists to generate new lead compounds for their research programmes to address unmet medical needs.”
As part of the collaboration, the company will apply its advanced technology platform, based on DNA-encoded library design, synthesis and screening, to identify new leads for targets of interest to Boehringer Ingelheim.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataBoehringer Ingelheim Research Germany senior vice-president Eric Haaksma said: “We are very excited about the opportunity to complement our in-house expertise in the field of small molecule therapeutics research with HitGen’s DNA encoded library platform.
“We believe that HitGen’s screening capabilities of huge chemical spaces in combination with Boehringer Ingelheim’s skills in optimising HitGen’s hits to novel drugs could speed-up the provision of innovative medicines.”
Under the deal, HitGen will be eligible for receiving upfront and milestone payments from Boehringer.
Specific financial details of the collaboration have not yet been disclosed.
